Abstract
Esophageal (EC) and gastric (GC) cancers represent severe global health issues. Within the last 18 months, the standard of care has significantly evolved for the first-line setting of advanced EC and GC within the field of human epidermal growth factor receptor 2 (HER2)-negative and HER2-positive patients. The breakthrough concepts for clinical practice of immune checkpoint inhibitors (ICIs) plus chemotherapy in both fields were presented at major oncology meetings over the last 2 years. This review summarizes the latest results on when and how to use the new combinations and highlights the unsolved issues in this new era.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
